Bladder Cancer, Version 3.2024 Featured Updates to the NCCN Guidelines

被引：90

作者：

Flaig, Thomas W. ^{[1
]}

Spiess, Philippe E. ^{[2
]}

Abern, Michael ^{[3
]}

Agarwal, Neeraj ^{[4
]}

Bangs, Rick

Buyyounouski, Mark K. ^{[5
]}

Chan, Kevin ^{[6
]}

Chang, Sam S. ^{[7
]}

Chang, Paul ^{[8
]}

Friedlander, Terence ^{[9
]}

Greenberg, Richard E. ^{[10
]}

Guru, Khurshid A. ^{[11
]}

Herr, Harry W. ^{[12
]}

Hoffman-Censits, Jean ^{[13
]}

Kaimakliotis, Hristos ^{[14
]}

Kishan, Amar U. ^{[15
]}

Kundu, Shilajit ^{[16
]}

Lele, Subodh M. ^{[17
]}

Mamtani, Ronac ^{[18
]}

Mian, Omar Y. ^{[19
,20
]}

Michalski, Jeff ^{[21
,22
]}

Montgomery, Jeffrey S. ^{[23
]}

Parikh, Mamta ^{[24
]}

Patterson, Anthony ^{[25
]}

Peyton, Charles ^{[26
]}

Plimack, Elizabeth R. ^{[10
]}

Preston, Mark A. ^{[27
]}

Richards, Kyle ^{[28
]}

Sexton, Wade J. ^{[2
]}

Siefker-Radtke, Arlene O. ^{[29
]}

Stewart, Tyler ^{[30
]}

Sundi, Debasish ^{[31
,32
]}

Tollefson, Matthew ^{[33
]}

Tward, Jonathan ^{[4
]}

Wright, Jonathan L. ^{[34
]}

Cassara, Carly J. ^{[35
]}

Gurski, Lisa A. ^{[35
]}

机构：

[1] Univ Colorado, Ctr Canc, Denver, CO 80202 USA

[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[3] Duke Canc Inst, Durham, NC USA

[4] Univ Utah, Huntsman Canc Inst, Biol, Salt Lake City, UT USA

[5] Stanford Canc Inst, Stanford, CA USA

[6] City Hope Natl Med Ctr, Monrovia, CA USA

[7] Vanderbilt Ingram Canc Ctr, Vanderbilt, TN 37232 USA

[8] UChicago Med, Comprehens Canc Ctr, Maywood, IL USA

[9] UCSF, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[10] Fox Chase Canc Ctr, Oreland, PA USA

[11] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[12] Mem Sloan Kettering Canc Ctr, Commack, NY USA

[13] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[14] Indiana Univ, Melvin & Bren Simon Comprehens Canc Ctr, Indianapolis, IN USA

[15] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

[16] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL USA

[17] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA

[18] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA

[19] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA

[20] Cleveland Clin, Taussig Canc Inst, Cleveland Hts, OH USA

[21] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA

[22] Washington Univ, Sch Med, St Louis, MO USA

[23] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI USA

[24] UC Davis, Comprehens Canc Ctr, Davis, AL USA

[25] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Germantown, TN USA

[26] UAB, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[27] Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA

[28] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[29] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[30] UC San, Diego Moores Canc Ctr, San Diego, CA USA

[31] Ohio State Univ, James Canc Hosp, Comprehens Canc Ctr, Columbus, OH USA

[32] Solove Res Inst, Columbus, OH USA

[33] Mayo Clin, Comprehens Canc Ctr, Dept Canc Biol, Jacksonville, FL USA

[34] Fred Hutchinson Canc Ctr, Sunnyside, WA USA

[35] Natl Comprehens Canc Network, Rockledge, PA USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2024年 / 22卷 / 04期

关键词：

BACILLUS-CALMETTE-GUERIN; MITOMYCIN-C; SINGLE-ARM; OPEN-LABEL; METAANALYSIS; PEMBROLIZUMAB; RECURRENCE; RISK; MULTICENTER; CARCINOMA;

D O I：

10.6004/jnccn.2024.0024

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bladder cancer, the sixth most common cancer in the United States, is most commonly of the urothelial carcinoma histologic subtype. The clinical spectrum of bladder cancer is divided into 3 categories that differ in prognosis, management, and therapeutic aims: (1) non - muscle-invasive bladder cancer (NMIBC); (2) muscle invasive, nonmetastatic disease; and (3) metastatic bladder cancer. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Bladder Cancer, including changes in the fifth edition of the WHO Classification of Tumours: Urinary and Male Genital Tumours and how the NCCN Guidelines aligned with these updates; new and emerging treatment options for bacillus Calmette-Guerin (BCG) -unresponsive NMIBC; and updates to systemic therapy recommendations for advanced or metastatic disease.

引用

页码：216 / 225

页数：10

共 47 条

[1]

American Urological Association, BCG shortage notice

[2]

[Anonymous], 2009, Prescribing information for TICE BCG live, for intravesical use

[3] Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends [J].

Antoni, Sebastien ;

Ferlay, Jacques ;

Soerjomataram, Isabelle ;

Znaor, Ariana ;

Jemal, Ahmedin ;

Bray, Freddie .

EUROPEAN UROLOGY, 2017, 71 (01) :96-108

[4] Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study [J].

Balar, Arjun, V ;

Kamat, Ashish M. ;

Kulkarni, Girish S. ;

Uchio, Edward M. ;

Boormans, Joost L. ;

Roumiguie, Mathieu ;

Krieger, Laurence E. M. ;

Singer, Eric A. ;

Bajorin, Dean F. ;

Grivas, Petros ;

Seo, Ho Kyung ;

Nishiyama, Hiroyuki ;

Konety, Badrinath R. ;

Li, Haojie ;

Nam, Kijoeng ;

Kapadia, Ekta ;

Frenkl, Tara ;

de Wit, Ronald .

LANCET ONCOLOGY, 2021, 22 (07) :919-930

[5] Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer:: A formal meta-analysis of comparative studies on recurrence and toxicity [J].

Böhle, A ;

Jocham, D ;

Bock, PR .

JOURNAL OF UROLOGY, 2003, 169 (01) :90-95

[6] Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial [J].

Boorjian, Stephen A. ;

Alemozaffar, Mehrdad ;

Konety, Badrinath R. ;

Shore, Neal D. ;

Gomella, Leonard G. ;

Kamat, Ashish M. ;

Bivalacqua, Trinity J. ;

Montgomery, Jeffrey S. ;

Lerner, Seth P. ;

Busby, Joseph E. ;

Poch, Michael ;

Crispen, Paul L. ;

Steinberg, Gary D. ;

Schuckman, Anne K. ;

Downs, Tracy M. ;

Svatek, Robert S. ;

Mashni, Joseph, Jr. ;

Lane, Brian R. ;

Guzzo, Thomas J. ;

Bratslavsky, Gennady ;

Karsh, Lawrence I. ;

Woods, Michael E. ;

Brown, Gordon ;

Canter, Daniel ;

Luchey, Adam ;

Lotan, Yair ;

Krupski, Tracey ;

Inman, Brant A. ;

Williams, Michael B. ;

Cookson, Michael S. ;

Keegan, Kirk A. ;

Andriole, Gerald L., Jr. ;

Sankin, Alexander I. ;

Boyd, Alan ;

O'Donnell, Michael A. ;

Sawutz, David ;

Philipson, Richard ;

Coll, Ruth ;

Narayan, Vikram M. ;

Treasure, F. Peter ;

Yla-Herttuala, Seppo ;

Parker, Nigel R. ;

Dinney, Colin P. N. .

LANCET ONCOLOGY, 2021, 22 (01) :107-117

[7] Cancer Susceptibility Mutations in Patients With Urothelial Malignancies [J].

Carlo, Maria I. ;

Ravichandran, Vignesh ;

Srinavasan, Preethi ;

Bandlamudi, Chaitanya ;

Kemel, Yelena ;

Ceyhan-Birsoy, Ozge ;

Mukherjee, Semanti ;

Mandelker, Diana ;

Chaim, Joshua ;

Knezevic, Andrea ;

Rana, Satshil ;

Fnu, Zarina ;

Breen, Kelsey ;

Arnold, Angela G. ;

Khurram, Aliya ;

Tkachuk, Kaitlyn ;

Cipolla, Catharine K. ;

Regazzi, Ashley ;

Hakimi, A. Ari ;

Al-Ahmadie, Hikmat ;

Dalbagni, Guido ;

Cadoo, Karen A. ;

Walsh, Michael F. ;

Teo, Min-Yuen ;

Funt, Samuel A. ;

Coleman, Jonathan A. ;

Bochner, Bernard H. ;

Iyer, Gopa ;

Solit, David B. ;

Stadler, Zsofia K. ;

Zhang, Liying ;

Rosenberg, Jonathan E. ;

Taylor, Barry S. ;

Robson, Mark E. ;

Berger, Michael F. ;

Vijai, Joseph ;

Bajorin, Dean F. ;

Offit, Kenneth .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)

[8]

Chalasani Venu, 2009, Can Urol Assoc J, V3, pS193

[9]

Chamie K, 2022, NEJM EVID, V2, DOI [10.1056/evidoa2200167, 10.1056/EVIDoa2200167]

[10] Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline [J].

Chang, Sam S. ;

Boorjian, Stephen A. ;

Chou, Roger ;

Clark, Peter E. ;

Daneshmand, Siamak ;

Konety, Badrinath R. ;

Pruthi, Raj ;

Quale, Diane Z. ;

Ritch, Chad R. ;

Seigne, John D. ;

Skinner, Eila Curlee ;

Smith, Norm D. ;

McKiernan, James M. .

JOURNAL OF UROLOGY, 2016, 196 (04) :1021-1029

← 1 2 3 4 5 →